Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
therapeutic approach
|
| gptkbp:amends |
chemical modifications
|
| gptkbp:associated_with |
clinical trials
patient outcomes safety concerns efficacy studies |
| gptkbp:can_be |
immune response
|
| gptkbp:delivers |
viral vectors
lipid nanoparticles naked RNA |
| gptkbp:has_a_focus_on |
biotechnology companies
pharmaceutical research |
| gptkbp:has_implications_for |
rare diseases
|
| https://www.w3.org/2000/01/rdf-schema#label |
RNA therapeutics
|
| gptkbp:includes |
gptkb:antisense_oligonucleotides
mRNA therapy siRNA therapy |
| gptkbp:influence |
traditional small molecule drugs
|
| gptkbp:is_a_subject_of |
market analysis
public interest scientific research regulatory scrutiny collaborative research investment opportunities patent applications ethical discussions clinical investigations commercialization efforts |
| gptkbp:is_designed_to |
in vitro transcription
|
| gptkbp:is_governed_by |
gptkb:FDA
EMA |
| gptkbp:is_part_of |
precision medicine
|
| gptkbp:is_studied_in |
genetic disorders
neurodegenerative diseases autoimmune diseases cancer treatment cardiovascular diseases viral infections |
| gptkbp:is_supported_by |
encapsulation
|
| gptkbp:is_used_in |
vaccination
combination therapies gene replacement gene silencing |
| gptkbp:produces |
HIV treatment
COVID-19 vaccines sickle cell disease treatment muscular dystrophy treatment cystic fibrosis treatment hemophilia_treatment |
| gptkbp:targets |
diseases
|
| gptkbp:uses |
RNA_molecules
|